With new features like an onboard high-resolution camera, integrated scanning wheels, and software connectivity, this device is going to be a game-changer for printers, converters, and ink suppliers.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here’s what to expect. Exact Sciences beat analysts’ revenue expectations by 2 ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations , with sales up 16% year on year to $811.1 million. The company’s ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Nearly a decade after the original Cologuard test received premarket approval from the FDA and became a blockbuster hit as a screening tool for colorectal cancer, its maker Exact Sciences is planning ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...